BioPharma Resources

Drug Trial Radar · NCT02536508

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

A Randomized, Double-Blind, Parallel-Group, 52-Week, Chronic-Dosing, Multi-Center Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Feb 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 627 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

627

Actual

Start

Aug 10, 2015

Primary completion

Sep 12, 2017

Study completion Sep 12, 2017

Sponsor

Lead sponsor
Pearl Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Conditions

  • COPD

Interventions

  • BGF MDI 320/14.4/9.6 μgDrug

    Budesonide, Glycopyrronium, and Formoterol Fumarate

  • GFF MDI 14.4/9.6 μgDrug

    Glycopyrronium and Formoterol Fumarate

  • BFF MDI 320/9.6 μgDrug

    Budesonide and Formoterol Fumarate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in BMD of the Lumbar SpineTime frame: at week 52
  2. Change From Baseline in the LOCS III (P) Score at Week 52Time frame: at week 52

Locations

64 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Dothan, Alabama

  • Research Site

    Jasper, Alabama

  • Research Site

    Peoria, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Fullerton, California

  • Research Site

    Gold River, California

  • Research Site

    Poway, California

  • Research Site

    Rolling Hills Estates, California

  • Research Site

    Sacramento, California

  • Research Site

    Clearwater, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Ormond Beach, Florida

  • Research Site

    Pensacola, Florida

  • Research Site

    Tamarac, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Dacula, Georgia

  • Research Site

    Norcross, Georgia

  • Research Site

    Rincon, Georgia

  • Research Site

    Edina, Minnesota

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Woodbury, Minnesota

  • Research Site

    Saint Charles, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Reno, Nevada

  • Research Site

    Albuquerque, New Mexico

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Gastonia, North Carolina

  • Research Site

    Greensboro, North Carolina

  • Research Site

    Hendersonville, North Carolina

  • Research Site

    Mooresville, North Carolina

  • Research Site

    Wilmington, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Columbus, Ohio

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.